Cell Therapy Tools for Cartilage Repair From Osteoarthritic Knee Joint of Elderly
A break through feat of growing pluripotency expressing cells from osteoarthritis (OA) affected cartilage tissue of knee joints of elderly has been reported by orthopedicians and cell culture experts led by Dr Shojiro Katoh, President, Edogawa Hospital. OA affects, knee joints of millions globally and those with severe disease, undergo Total Knee Arthroplasty (TKA), in which damaged cartilage is replaced with artificial knee prosthesis. Dr Katoh, during TKA surgery, took portions of the damaged tissue, which otherwise is discarded, isolated chondrocyte cells in tissue engineering lab, and could culture them as fully reorganized healthy cartilage tissue, expressing biomarkers relevant to pluripotency.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200617005880/en/
"Pluripotency expressing cells grown from osteoarthritis affected knee joint, open doors to a spectrum of novel solutions to address cartilage damage," says Dr. Shojiro Katoh, President, Edogawa Hospital, Tokyo, Japan. (Photo: Business Wire)
Cartilage of the knee joint acts as a cushion between bones of the thigh and leg and absorbs the body weight. When cartilage is damaged due to sports injury, trauma or wear and tear, it causes joint pain and disability. In early stage of the disease, Autologous Chondrocyte Implantation (ACI) or Matrix Assisted Chondrocyte Implantation (MACI) are practiced. Such cell therapies use patient’s own cartilage cells, harvested from healthy, non-weight bearing area, grown in lab, and transplanted to replace the damaged tissue, to restore functionality.
"This could probably be the world’s first report of Osteoarthritis tissue, yielding cells expressing pluripotency markers," said Dr. Katoh, citing their publication in Regenerative Therapy Journal (https://www.sciencedirect.com/science/article/pii/S2352320420300274), also presented in the 19th Japanese society for regenerative medicine meeting. "Our technique may help utilize OA affected cartilage, discarded as biomedical waste, as a source of tools of cell therapies viz., cells, cell secreted growth factors, and exosomes to repair cartilage defects in regenerative medicine," he added.
Edogawa hospital, located in eastern Tokyo, has many senior citizens. "Contrary to the age-old belief that Wisdom is the strength of elders, this research finding has made me humble, to learn about nature’s hidden strength in their physical intricacies too, fueling our enthusiasm," said Dr Katoh adding a philosophical humility to his accomplishment. His Edogawa Evolutionary Lab of Science (EELS), having confirmed hyaline phenotype is now evaluating miRNA-140 and Hyaluronan expression of chondrocytes.
This technology has a potential to solve cartilage damage of approximately 12 million people annually worldwide, according to JBM Inc, and GN Corporation, co-applicants to a patent and research partners to EELS.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200617005880/en/
Contact information
Samuel JK Abraham
GN Corporation
info@gncorporation.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 04:41:00 EET | Press release
Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution for intravenous infusion. “The new SteQeyma™ autoinjector brings together convenience and practical usability to meet the everyday challenges faced by patients living with chronic inflammatory diseases. The full range of our SteQeyma™ dosage forms and strengths, with the autoinjector now added, provides patients and healthcare professionals with more individualized treatm
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 03:15:00 EET | Press release
Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly three years, while adding a seasoned in-country team spanning operations, support, sales, finance, and leadership to enable rapid integration and future growth. The E
IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 23:10:00 EET | Press release
IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerstone of IonQ’s global strategy,” said Niccolo de Masi, Chairman and CEO of IonQ. “QuantumBasel continues to be a critical innovation node for our company as
Suzano Starts Up New Production Line, Boosting Its Fluff Pulp Capacity by 400%17.12.2025 22:50:00 EET | Press release
Suzano, the world’s largest pulp producer, has commenced operations this week at its new fluff pulp production line located in its Limeira unit in Brazil’s São Paulo state. This R$490 million investment increases Suzano’s total fluff pulp production capacity by more than 400%, from 100,000 to 440,000 tonnes per year. The project involved converting the existing pulp line at the Limeira unit into a flexible machine, capable of producing both Eucafluff® and market pulp. Eucafluff® is used in the production of absorbent and personal hygiene products, such as baby and adult diapers, sanitary pads and pet pads. Then market pulp is supplied for making products including toilet paper, printing and writing papers, and paper packaging. Launched in 2015, Eucafluff® is the world’s first fluff pulp made from eucalyptus, delivering unique advantages like enhanced softness and flexibility, which translate into thinner, more discreet and comfortable products. Its high compression capability enables s
SES Acknowledges Moody’s Rating Action and Reiterates Deleveraging Commitments17.12.2025 22:36:00 EET | Press release
SES S.A. (“SES” or the “Company”), a leading space solutions company, acknowledges the credit rating action announced by Moody’s Investor Service today, which follows the release of SES’ Q3 2025 results and Intelsat integration update. SES management reiterates that the Company continues to execute on its strategy with a clear plan to strengthen its key credit metrics over time. Consistent with this plan, it remains management’s intention to de-lever and return to credit metrics that are commensurate with investment grade, with a policy objective of reducing adjusted net leverage1 to at least 3.0x or below. Today’s rating action does not change the Company’s ability to operate its business, serve customers, or execute its strategic plan. SES maintains a balanced weighted average debt maturity profile of approximately five years, and the rating action from Moody’s is not expected to have a material impact on the interest payable under the Company’s existing debt facilities. SES also ben
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom